Lupin Limited – Product Pipeline Review

Global Markets Direct’s, ‘Lupin Limited – Product Pipeline Review, 2016’, provides an overview of the Lupin Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lupin Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Lupin Limited

The report provides overview of Lupin Limited including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Lupin Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Lupin Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Lupin Limited’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lupin Limited

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lupin Limited’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Lupin Limited Snapshot 6

Lupin Limited Overview 6

Key Information 6

Key Facts 6

Lupin Limited - Research and Development Overview 7

Key Therapeutic Areas 7

Lupin Limited - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Lupin Limited - Pipeline Products Glance 12

Lupin Limited - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Lupin Limited - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Lupin Limited - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Lupin Limited - Unknown Stage Pipeline Products 17

Unknown Products/Combination Treatment Modalities 17

Lupin Limited - Drug Profiles 18

Biosimilar for Oncology 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

etanercept biosimilar 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

LND-101001 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

LNP-1892 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Small Molecule for Colon and Lung Cancer 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Biosimilar for Diabetes 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Biosimilar for Inflammation 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Biosimilar for Ophthalmology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Biosimilar for Viral Infections 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Autoimmune Diseases 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule for Infectious Diseases 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule for Pain and Inflammation 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Biosimilar for Endocrinology 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Lupin Limited - Pipeline Analysis 32

Lupin Limited - Pipeline Products by Target 32

Lupin Limited - Pipeline Products by Route of Administration 33

Lupin Limited - Pipeline Products by Molecule Type 34

Lupin Limited - Pipeline Products by Mechanism of Action 35

Lupin Limited - Recent Pipeline Updates 36

Lupin Limited - Dormant Projects 37

Lupin Limited - Company Statement 38

Lupin Limited - Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Lupin Limited, Key Information 6

Lupin Limited, Key Facts 6

Lupin Limited – Pipeline by Indication, 2016 9

Lupin Limited – Pipeline by Stage of Development, 2016 10

Lupin Limited – Monotherapy Products in Pipeline, 2016 11

Lupin Limited – Phase III, 2016 12

Lupin Limited – Phase II, 2016 13

Lupin Limited – Phase I, 2016 14

Lupin Limited – Preclinical, 2016 15

Lupin Limited – Discovery, 2016 16

Lupin Limited – Unknown, 2016 17

Lupin Limited – Pipeline by Target, 2016 32

Lupin Limited – Pipeline by Route of Administration, 2016 33

Lupin Limited – Pipeline by Molecule Type, 2016 34

Lupin Limited – Pipeline Products by Mechanism of Action, 2016 35

Lupin Limited – Recent Pipeline Updates, 2016 36

Lupin Limited – Dormant Developmental Projects,2016 37

Lupin Limited, Other Locations 39

Lupin Limited, Subsidiaries 40

List of Figures

List of Figures

Lupin Limited – Pipeline by Top 10 Indication, 2016 8

Lupin Limited – Pipeline by Stage of Development, 2016 10

Lupin Limited – Monotherapy Products in Pipeline, 2016 11

Lupin Limited – Pipeline by Target, 2016 32

Lupin Limited – Pipeline by Route of Administration, 2016 33

Lupin Limited – Pipeline by Molecule Type, 2016 34

Lupin Limited – Pipeline Products by Mechanism of Action, 2016 35

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared